期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 63, 期 10-11, 页码 943-955出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2011.05.021
关键词
Adjuvant; Cancer; Vaccine; PLGA
资金
- Canadian Health Institute of Research [MOP 42407]
- Natural Sciences and Engineering Council of Canada [STPGP 336987]
Development of safe and effective cancer vaccine formulation is a primary focus in the field of cancer immunotherapy. The recognition of the crucial role of dendritic cells (DCs) in initiating anti-tumor immunity has led to the development of several strategies that target vaccine antigens to DCs as an attempt for developing potent, specific and lasting anti-tumor T cell responses. The main objective of this review is to provide an overview on the application of poly (D,L-lactic-co-glycolic acid) nanoparticles (PLGA-NPs) as cancer vaccine delivery system and highlight their potential in the development of future therapeutic cancer vaccines. PLGA-NPs containing antigens along with immunostimulatory molecules (adjuvants) can not only target antigen actively to DCs, but also provide immune activation and rescue impaired DCs from tumor-induced immuosupression. (C) 2011 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据